Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Högenauer, C; Langner, C; Lipp, RW; Höfler, G; Krejs, GJ; Hinterleitner, TA.
Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation.
Eur J Gastroenterol Hepatol. 2003; 15(3):323-327
Doi: 10.1097/01.meg.0000050013.68425.10
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Hoegenauer Christoph
- Co-Autor*innen der Med Uni Graz
- Hinterleitner Thomas
- Höfler Gerald
- Krejs Günter Josef
- Langner Cord
- Lipp Rainer
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We report a 51-year-old man with an advanced malignant metastatic gastrointestinal stromal tumour, who showed a complete response after 5 months of treatment with imatinib at a dose of 400 mg per day. An early treatment response was demonstrated in an 18fluorodeoxyglucose positron emission tomography scan after 1 month of therapy. Complete remission was documented histologically by negative serial biopsies of residual tumour nodes after 5 months of therapy. No serious side effects were seen with imatinib. A 21 bp, exon 11, in-frame mutation of the c-kit gene was found by DNA sequence analysis of tumour tissue.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Agents - therapeutic use
- Benzamides -
- Enzyme Inhibitors - therapeutic use
- Gastrointestinal Neoplasms - drug therapy
- Gastrointestinal Neoplasms - genetics
- Humans -
- Imatinib Mesylate -
- Male -
- Mesenchymoma - drug therapy
- Mesenchymoma - genetics
- Mesenchymoma - secondary
- Middle Aged -
- Mutation -
- Piperazines - therapeutic use
- Protein-Tyrosine Kinases - antagonists & inhibitors
- Pyrimidines - therapeutic use
- Remission Induction -
- Find related publications in this database (Keywords)
- antineoplastic agents
- neoplasms connective and soft tissue
- protein-tyrosine kinase
- gastrointestinal neoplasms
- case report
- fluorodeoxyglucose F18
- tomography
- emission-computed
- enzyme inhibitors